Compare Canopy Growth Corp (CGC) vs Freeport-McMoRan Inc (FCX) Price & Performance

CGC trades at $1.01, up 1.0% in the last session, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 fiscal 2027 revenue growth of 13% year-over-year, beating estimates, yet continues to post net losses. Recent news highlights expansion in European medical cannabis markets and cost-cutting efforts, while analyst consensus is mixed with 33% buy ratings.

Outlook remains speculative with high execution risk; improving cash flow trends and potential U.S. rescheduling offer upside, but persistent negative margins and debt concerns weigh on equity value. Investors should weigh growth prospects against profitability challenges in the volatile cannabis sector.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.